A study comparing IBD patients receiving vedolizumab versus anti-tumor necrosis factor (anti-TNF) therapies found that patients with UC receiving vedolizumab were more likely to develop PG compared to patients treated with anti-TNF agents [5]. The gene discussed is TNF; the disease is inflammatory bowel disease.